Brainstorm Cell Therapeutics Inc. (NASDAQ:BCLI) Q1 2022 Earnings Conference Call May 16, 2022 8:00 AM ET

Company Participants

Tom Galassi - Investor Relations, LifeSci Advisors

Chaim Lebovits - Chief Executive Officer

Alla Patlis - Interim Chief Financial Officer

Stacy Lindborg - Executive Vice President and Chief Development Officer

Ralph Kern - President and Chief Medical Officer

David Setboun - Executive Vice President and Chief Operating Officer

Conference Call Participants

David Bautz - Zacks Small-Cap Research

Michelle Lorenz - Voices for ALS

Operator

Greetings and welcome to the Brainstorm Cell Therapeutics First Quarter 2022 Conference Call. At this time, participants are in a listen-only mode. As a reminder, this call is being recorded.

And I would now like to introduce your host for today's conference, Tom Galassi of LifeSci Advisors. Mr. Galassi, you may begin.

Tom Galassi

Good morning and thank you for joining us. Before we begin the opening remarks, we would like to remind listeners that this conference call contains numerous statements, descriptions, forecasts, and projections regarding Brainstorm Cell Therapeutics and its potential future operations and performance, statements regarding the market potential for the treatment of neurodegenerative orders, such as ALS and MS, the sufficiency of the company's existing capital resources for continuing operations in 2022 and beyond, the safety and clinical effectiveness of the NurOwn technology platform, clinical trials of NurOwn and related clinical development programs, and the company's ability to develop strategic collaborations and partnerships to support their business planning efforts.

Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond Brainstorm's control, including the risks and uncertainties described from time-to-time in its SEC filings. The company's results may differ materially from those presented on today's call. The company undertakes no obligation to publicly update any forward-looking statements.

Joining me on the call today will be Chaim Lebovits, CEO of Brainstorm; and Alla Patlis, Interim Chief Financial Officer. In addition, Dr. Stacy Lindborg, Executive Vice President and Chief Development Officer; Dr. Ralph Kern, President and Chief Medical Officer; and Dr. David Setboun, Executive Vice President and Chief Operating Officer, are also on the call and will be available to answer your questions during the Q&A session.

Now, I would like to turn the call over to Mr. Lebovits. Please go ahead.

Chaim Lebovits

Thanks, Tom. Thank you to all listening for joining us to discuss our first quarter financial results and corporate highlights. Given that we provided the detailed update in our clinical programs during our year-end call only about six weeks ago, I'll keep my prepared remarks brief today as is our usual practice we'll follow our prepared remarks to addressing questions we received from investors and advance, as well as taking live questions from those of you listening on the call today.